Possible molecular target therapy with rapamycin in MDS

Area of Science:

• Molecular Biology
• Genetics
• Oncology

Background:

• Myelodysplastic Syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
• Glutathione S-transferases theta (GSTT)-1 gene mutations have been observed in MDS patients.
• A specific 123 bp deletion in GSTT-1 creates a mutant form homologous to mammalian target of rapamycin (mTOR).

Purpose of the Study:

• To analyze the functional consequences of the mutant GSTT-1 gene.
• To investigate the effect of rapamycin on wild-type and mutant GSTT-1 expression in MDS.
• To determine if rapamycin exhibits selective toxicity towards cells expressing the mutant GSTT-1 gene.

Main Methods:

• Establishment of stable transformants expressing either wild-type or mutant GSTT-1 genes.
• Reverse Transcription Polymerase Chain Reaction (RT-PCR) to analyze gene expression.
• Treatment of stable transformants and MDS bone marrow cells with rapamycin.

Main Results:

• Rapamycin exposure caused the disappearance of the mutant GSTT-1 gene band in RT-PCR analysis.
• The wild-type GSTT-1 gene band remained unaffected by rapamycin treatment.
• This selective effect was observed in both engineered cell lines and patient-derived bone marrow cells.

Conclusions:

• Rapamycin demonstrates selective activity against clones expressing the mutant GSTT-1 gene.
• This suggests a potential targeted therapeutic approach for MDS by exploiting the GSTT-1 mutation.
• Further research is warranted to explore rapamycin's efficacy and safety in MDS treatment.